Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma

Hematology/Oncology Clinics of North America

Volumn 25, Issue 4, 2011, Pages 765-791

  Smaldone, Marc C ^a   Fung, Chunkit ^b   Uzzo, Robert G ^a   Haas, Naomi B ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adjuvant; Neoadjuvant; Prognosis; Renal cell carcinoma; Targeted therapy

Indexed keywords

AXITINIB; BEVACIZUMAB; CARBONATE DEHYDRATASE IX; EPITHELIAL CELL ADHESION MOLECULE; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GELSOLIN; GIRENTUXIMAB; HYPOXIA INDUCIBLE FACTOR; INTERLEUKIN 2; KI 67 ANTIGEN; MEDROXYPROGESTERONE ACETATE; PAZOPANIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; TIVOZANIB; TUMOR CELL VACCINE; UFT; VIMENTIN; VON HIPPEL LINDAU PROTEIN;

ADJUVANT THERAPY; ANGIOGENESIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; DNA METHYLATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; LUNG METASTASIS; OVERALL SURVIVAL; PARTIAL NEPHRECTOMY; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; UPREGULATION;

CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY NEOPLASMS; NEOADJUVANT THERAPY; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RISK FACTORS;

EID: 79960341785     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2011.06.002     Document Type: Review

References (130)

1. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277.
2. Chow W.H., Devesa S.S., Warren J.L., et al. Rising incidence of renal cell cancer in the United States. JAMA 1999, 281:1628.
3. Hollingsworth J.M., Miller D.C., Daignault S., et al. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 2006, 98:1331.
4. Jayson M., Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology 1998, 51:203.
5. Frank I., Blute M.L., Leibovich B.C., et al. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol 2005, 173:1889.
6. Huang W.C., Levey A.S., Serio A.M., et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006, 7:735.
7. McKiernan J., Simmons R., Katz J., et al. Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology 2002, 59:816.
8. Go A.S., Chertow G.M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296.
9. Huang W.C., Elkin E.B., Levey A.S., et al. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors-is there a difference in mortality and cardiovascular outcomes?. J Urol 2009, 181:55.
10. Thompson R.H., Boorjian S.A., Lohse C.M., et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol 2008, 179:468.
11. Gill I.S., Kavoussi L.R., Lane B.R., et al. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol 2007, 178:41.
12. Hafez K.S., Fergany A.F., Novick A.C. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol 1999, 162:1930.
13. Lam J.S., Shvarts O., Leppert J.T., et al. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005, 173:1853.
14. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001, 345:1655.
15. Fallick M.L., McDermott D.F., LaRock D., et al. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 1997, 158:1691.
16. Mickisch G.H., Garin A., van Poppel H., et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001, 358:966.
17. Wolf J.S., Aronson F.R., Small E.J., et al. Nephrectomy for metastatic renal cell carcinoma: a component of systemic treatment regimens. J Surg Oncol 1994, 55:7.
18. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125.
19. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115.
20. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295:2516.
21. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:2505.
22. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103.
23. Tsui K.H., Shvarts O., Smith R.B., et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000, 163:1090.
24. Lam J.S., Shvarts O., Leppert J.T., et al. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 2005, 174:466.
25. Kunkle D.A., Haas N.B., Uzzo R.G. Adjuvant therapy for high-risk renal cell carcinoma patients. Curr Urol Rep 2007, 8:19.
26. Eggener S.E., Yossepowitch O., Pettus J.A., et al. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol 2006, 24:3101.
27. Levy D.A., Slaton J.W., Swanson D.A., et al. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998, 159:1163.
28. Sandock D.S., Seftel A.D., Resnick M.I. A new protocol for the follow-up of renal cell carcinoma based on pathological stage. J Urol 1995, 154:28.
29. Stephenson A.J., Chetner M.P., Rourke K., et al. Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol 2004, 172:58.
30. Hafez K.S., Novick A.C., Campbell S.C. Patterns of tumor recurrence and guidelines for follow-up after nephron sparing surgery for sporadic renal cell carcinoma. J Urol 1997, 157:2067.
31. Pantuck A.J., Zisman A., Belldegrun A.S. The changing natural history of renal cell carcinoma. J Urol 2001, 166:1611.
32. Janzen N.K., Kim H.L., Figlin R.A., et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003, 30:843.
33. Adamy A., Chong K.T., Chade D., et al. Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma. J Urol 2011, 185:433.
34. Ljungberg B., Alamdari F.I., Rasmuson T., et al. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 1999, 84:405.
35. Motzer R.J., Bukowski R.M. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006, 24:5601.
36. Fyfe G., Fisher R.I., Rosenberg S.A., et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995, 13:688.
37. Boorjian S.A., Crispen P.L., Lohse C.M., et al. Surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma following nephrectomy. J Urol 2008, 180:99.
38. Russo P., Synder M., Vickers A., et al. Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer. ScientificWorldJournal 2007, 7:768.
39. Lane B.R., Kattan M.W., Novick A.C. Prediction models of renal cell carcinoma 2006, AUA Update Series 25. American Urological Association, p. 57.
40. Motzer R.J., Bacik J., Schwartz L.H., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004, 22:454.
41. Shuch B., La Rochelle J.C., Wu J., et al. Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance. Cancer 2008, 113:1324.
42. Santos Arrontes D., Fernandez Acenero M.J., Garcia Gonzalez J.I., et al. Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index. J Urol 2008, 179:857.
43. Kim H.L., Belldegrun A.S., Freitas D.G., et al. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol 2003, 170:1742.
44. Kontak J.A., Campbell S.C. Prognostic factors in renal cell carcinoma. Urol Clin North Am 2003, 30:467.
45. Johnson T.V., Abbasi A., Owen-Smith A., et al. Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma. J Urol 2010, 183:480.
46. AJCC: kidney 2010, 479. Springer, New York. 7th edition. (AJCC Cancer Staging Manual). S.B. Edge, D.R. Byrd, C.C. Compton (Eds.).
47. Leibovich B.C., Lohse C.M., Crispen P.L., et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 2010, 183:1309.
48. Katz M.D., Serrano M.F., Grubb R.L., et al. Percent microscopic tumor necrosis and survival after curative surgery for renal cell carcinoma. J Urol 2010, 183:909.
49. Cangiano T., Liao J., Naitoh J., et al. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol 1999, 17:523.
50. Klatte T., Said J.W., de Martino M., et al. Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification. J Urol 2009, 181:1558.
51. Ficarra V., Martignoni G., Maffei N., et al. Original and reviewed nuclear grading according to the Fuhrman system: a multivariate analysis of 388 patients with conventional renal cell carcinoma. Cancer 2005, 103:68.
52. Smaldone M.C., Maranchie J.K. Clinical implications of hypoxia inducible factor in renal cell carcinoma. Urol Oncol 2009, 27:238.
53. Wood C.G. Molecular markers of prognosis in renal cell carcinoma: insight into tumor biology helps define risk and provides targets for therapy. J Surg Oncol 2006, 94:264.
54. Atkins M., Regan M., McDermott D., et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005, 11:3714.
55. Bui M.H., Seligson D., Han K.R., et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003, 9:802.
56. Davis I.D., Wiseman G.A., Lee F.T., et al. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immun 2007, 7:13.
57. Divgi C.R., Pandit-Taskar N., Jungbluth A.A., et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 2007, 8:304.
58. Uzzo R.G., Russo P., Chen D., et al. The multicenter phase III redect trial: a comparative study of 124 I-girentuximab-PET/CT versus diagnostic CT for the pre-operative diagnosis of clear cell Renal Cell Carcinoma (ccRCC) 2010, late breaking abstract, AUA, San Francisco (CA).
59. Bui M.H., Visapaa H., Seligson D., et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol 2004, 171:2461.
60. Kim H.L., Seligson D., Liu X., et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 2005, 173:1496.
61. Kim H.L., Seligson D., Liu X., et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 2004, 10:5464.
62. Lam J.S., Leppert J.T., Figlin R.A., et al. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 2005, 66:1.
63. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3:415.
64. Gonzalgo M.L., Yegnasubramanian S., Yan G., et al. Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis. Clin Cancer Res 2004, 10:7276.
65. Dulaimi E., Ibanez de Caceres I., Uzzo R.G., et al. Promoter hypermethylation profile of kidney cancer. Clin Cancer Res 2004, 10:3972.
66. Uzzo R.G. Renal masses-to treat or not to treat? If that is the question are contemporary biomarkers the answer?. J Urol 2008, 180:433.
67. Lane B.R., Kattan M.W. Prognostic models and algorithms in renal cell carcinoma. Urol Clin North Am 2008, 35:613.
68. Lane B.R., Babineau D., Kattan M.W., et al. A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J Urol 2007, 178:429.
69. Jeldres C., Sun M., Liberman D., et al. Can renal mass biopsy assessment of tumor grade be safely substituted for by a predictive model?. J Urol 2009, 182:2585.
70. Kutikov A., Uzzo R.G. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol 2009, 182:844.
71. Kutikov A., Manley B.J., Canter D.J., et al. Anatomical features of enhancing renal masses predict histology and grade - an analysis using nephrometry (AUA abstract no. 1238). J Urol 2010, 183:e479.
72. Lane B.R., Samplaski M.K., Herts B.R., et al. Renal mass biopsy-a renaissance?. J Urol 2008, 179:20.
73. Kutikov A., Egleston B.L., Wong Y.N., et al. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol 2010, 28:311.
74. Kutikov A, Egleston BL, Smaldone MC, et al. Quantification of competing risks of death with localized renal cell carcinoma (RCC): a comprehensive nomogram incorporating co-morbidities Podium presentation; American Urologic Association meeting. Washington, May, 2011.
75. Yaycioglu O., Roberts W.W., Chan T., et al. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology 2001, 58:141.
76. Cindolo L., de la Taille A., Messina G., et al. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int 2003, 92:901.
77. Raj G.V., Thompson R.H., Leibovich B.C., et al. Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol 2008, 179:2146.
78. Kattan M.W., Reuter V., Motzer R.J., et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001, 166:63.
79. Sorbellini M., Kattan M.W., Snyder M.E., et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005, 173:48.
80. Frank I., Blute M.L., Cheville J.C., et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002, 168:2395.
81. Ficarra V., Martignoni G., Lohse C., et al. External validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma. J Urol 2006, 175:1235.
82. Leibovich B.C., Blute M.L., Cheville J.C., et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003, 97:1663.
83. Patard J.J., Kim H.L., Lam J.S., et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 2004, 22:3316.
84. Zisman A., Pantuck A.J., Dorey F., et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001, 19:1649.
85. Zisman A., Pantuck A.J., Wieder J., et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002, 20:4559.
86. Leibovich B.C., Han K.R., Bui M.H., et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003, 98:2566.
87. Motzer R.J., Bacik J., Murphy B.A., et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289.
88. Cindolo L., Patard J.J., Chiodini P., et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer 2005, 104:1362.
89. Finney R. The value of radiotherapy in the treatment of hypernephroma-a clinical trial. Br J Urol 1973, 45:258.
90. Kjaer M., Frederiksen P.L., Engelholm S.A. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys 1987, 13:665.
91. Pizzocaro G., Piva L., Di Fronzo G., et al. Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J Urol 1987, 138:1379.
92. Naito S., Kumazawa J., Omoto T., et al. Postoperative UFT adjuvant and the risk factors for recurrence in renal cell carcinoma: a long-term follow-up study. Kyushu University Urological Oncology Group. Int J Urol 1997, 4:8.
93. Yang J.C., Sherry R.M., Steinberg S.M., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003, 21:3127.
94. Clark J.I., Atkins M.B., Urba W.J., et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003, 21:3133.
95. Galligioni E., Quaia M., Merlo A., et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer 1996, 77:2560.
96. Messing E.M., Manola J., Wilding G., et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003, 21:1214.
97. Pizzocaro G., Piva L., Colavita M., et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001, 19:425.
98. Atzpodien J., Schmitt E., Gertenbach U., et al. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 2005, 92:843.
99. Margulis V., Matin S.F., Tannir N., et al. Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology 2009, 73:337.
100. Jocham D., Richter A., Hoffmann L., et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004, 363:594.
101. May M., Brookman-May S., Hoschke B., et al. Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunol Immunother 2010, 59:687.
102. Wood C., Srivastava P., Bukowski R., et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008, 372:145.
103. Davis I.D., Liu Z., Saunders W., et al. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. Cancer Immun 2007, 7:14.
104. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:16.
105. Sternberg C.N., Davis I.D., Mardiak J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061.
106. Rini B.I., Wilding G., Hudes G., et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009, 27:4462.
107. Rixe O., Bukowski R.M., Michaelson M.D., et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007, 8:975.
108. Bhargava P., Esteves B., Al-Adhami M., et al. Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): subgroup analysis from a phase II randomized discontinuation trial (RDT). J Clin Oncol 2010, 28. 15 [abstract: 4599].
109. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449.
110. Rabets J.C., Kaouk J., Fergany A., et al. Laparoscopic versus open cytoreductive nephrectomy for metastatic renal cell carcinoma. Urology 2004, 64:930.
111. Krambeck A.E., Leibovich B.C., Lohse C.M., et al. The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma. J Urol 2006, 176:1990.
112. Shuch B., Riggs S.B., LaRochelle J.C., et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int 2008, 102:692.
113. Wood C.G. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res 2007, 13:697s.
114. Rathmell W.K., Pruthi R., Wallen E. Neoadjuvant treatment of renal cell carcinoma. Urol Oncol 2010, 28:69.
115. Wagner J.R., Walther M.M., Linehan W.M., et al. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol 1999, 162:43.
116. Klatte T., Ittenson A., Rohl F.W., et al. Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial. Br J Cancer 2006, 95:1167.
117. Zielinski H., Szmigielski S., Petrovich Z. Comparison of preoperative embolization followed by radical nephrectomy with radical nephrectomy alone for renal cell carcinoma. Am J Clin Oncol 2000, 23:6.
118. Rothman J., Egleston B., Wong Y.N., et al. Histopathological characteristics of localized renal cell carcinoma correlate with tumor size: a SEER analysis. J Urol 2009, 181:29.
119. Amin C., Wallen E., Pruthi R.S., et al. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology 2008, 72:864.
120. Margulis V., Matin S.F., Tannir N., et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 2008, 180:94.
121. Thomas A.A., Rini B.I., Stephenson A.J., et al. Surgical resection of renal cell carcinoma after targeted therapy. J Urol 2009, 182:881.
122. Wood C.G., Margulis V. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer 2009, 115:2355.
123. Jonasch E., Wood C.G., Matin S.F., et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:4076.
124. Chapin B.F., Delacroix S.E., Culp S.H., et al. Postoperative complications from cytoreductive nephrectomy after neoadjuvant targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2011, 29. 7 [abstract: 300].
125. Thomas A.A., Rini B.I., Lane B.R., et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 2009, 181:518.
126. Hellenthal N.J., Underwood W., Penetrante R., et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol 2010, 184:859.
127. Cowey C.L., Amin C., Pruthi R.S., et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 2010, 28:1502.
128. Salem M., Shah S.N., Wood L.S., et al. Contrast enhanced CT (CE-CT) changes and nephrometry down-scoring of unresectable primary renal cell carcinoma (RCC) tumors in patients (Pts) treated with neoadjuvant sunitinib. J Clin Oncol 2011, 29. 7 [abstract: 299].
129. Rodriguez Faba O., Breda A., Rosales A., et al. Neoadjuvant temsirolimus effectiveness in downstaging advanced non-clear cell renal cell carcinoma. Eur Urol 2010, 58:307.
130. Karam J.A., Rini B.I., Varella L., et al. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol 2011, 185:439.